WCG acquires clinical trial solutions provider Trifecta Clinical

US-based clinical service company WCG has acquired Trifecta Clinical, a provider of technology-enabled clinical trial solutions for an undisclosed price.

The acquisition includes Trifecta Clinical’s site communication platform InvestigatorSpace, virtual training programs, and also safety documentation services.

WCG provides solutions for improving the quality and efficiency of clinical research.

The acquisition of Trifecta will expand the variety of specialized services and solutions offered by WCG. Besides, it will improve WCG’s ability to connect sites, sponsors, and clinical research organizations (CROs) across the clinical trials ecosystem.

Donald A. Deieso – Executive Chairman and CEO of WCG said: “With a host of services that fully integrate clinical trial training and communication, from safety letter notification to regulatory document exchange, Trifecta adds another dimension to WCG’s compelling value proposition.

“This acquisition is part of our effort to pursue strategic opportunities that allow us to expand and enhance our offerings in anticipation of our customers’ needs. We’re pleased to be joining forces with an innovative company such as Trifecta and working together to help sponsors, CROs, and clinical research sites increase efficiency and the quality of the work they do every day.”

Going forward, Trifecta Clinical will operate as WCG Trifecta. Its leadership structure will be retained along with its headquarters located in Los Angeles, and its other locations in Indianapolis, Philadelphia, and Osaka, Japan.

Dave Young – Trifecta Clinical Founder and CEO said: “We’re thrilled to be joining WCG, a company that shares our passion for improving the clinical trial process by delivering impactful solutions to age-old problems. This acquisition was a natural evolution for Trifecta. Now as part of WCG, we can help our customers by continuing to provide perpetual innovation, rooted in unrivaled expertise.”

Related posts

• G1 Therapeutics gets Cosela FDA approval to reduce chemotherapy-induced bone marrow suppression (0)
• Targovax gets FDA fast track status for ONCOS-102 in malignant pleural mesothelioma (0)
• Boston Scientific to take full ownership of Preventice Solutions (0)
• DJO acquires orthopedic implants provider Trilliant Surgical (0)
• Bexson Biomedical raises $4.8m in Series A round for subcutaneous ketamine treatment platform (0)
• Horizon Therapeutics to acquire Viela Bio for $3bn to grow rare disease portfolio (0)
• Philips to acquire medical device integration firm Capsule Technologies for $635m (0)
• Hillrom to acquire CAM patch developer Bardy Diagnostics for $375m (0)
• US FDA approves Opdivo, Cabometyx combo for advanced renal cell carcinoma (0)
• ViiV Healthcare secures Cabenuva FDA approval for HIV-1 treatment (0)